Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 8/20 | 0.62 |
| ▸ | ICMT | O60725 | 8/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858064 | 1.00 | ADAM17 (0.62) | ADAM17ICMTMMP2MMP13MMP14 | |
| SCHEMBL3847978 | 0.90 | ADAM17 (0.61) | ADAM17MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL3847973 | 0.90 | ADAM17 (0.61) | ADAM17MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL3849409 | 0.90 | ADAM17 (0.63) | ADAM17ICMTALDH1A1LMNAKMT2A | |
| SCHEMBL3849402 | 0.90 | ADAM17 (0.63) | ADAM17ICMTALDH1A1LMNAKMT2A | |
| SCHEMBL3852584 | 0.87 | ADAM17 (0.49) | ADAM17ICMTMMP2MMP13MMP14 | |
| SCHEMBL3853676 | 0.87 | ADAM17 (0.56) | ADAM17MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL3852590 | 0.87 | ADAM17 (0.49) | ADAM17ICMTMMP2MMP13MMP14 | |
| SCHEMBL3853689 | 0.87 | ADAM17 (0.56) | ADAM17MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL9584364 | 0.85 | ADAM17 (0.58) | ADAM17ICMTALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576222-B2 | N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | ADAM17, TPSAB1, ADAM10 | ADAM17 1/4885ICMT 3225/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.